Treatment for Advanced and Recurrent Endometrial Carcinoma: Combined Modalities
- 21 July 2010
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 15 (8), 852-861
- https://doi.org/10.1634/theoncologist.2010-0091
Abstract
Learning Objectives: After completing this course, the reader will be able to: Discuss the role of radiation therapy for advanced stage endometrial cancer in order to differentiate between patients who should receive only radiation therapy and patients requiring surgery and/or chemotherapy in addition to radiation.Evaluate the role of surgery for stage IV and recurrent endometrial cancer in order to select patients most likely to benefit from cytoreductive surgery.Evaluate the role of chemotherapy, particularly in conjunction with radiotherapy, in advanced stage endometrial carcinoma and select appropriate candidates for multimodality therapy. CME This article is available for continuing medical education credit at CME.TheOncologist.com Women with recurrent or advanced endometrial cancer constitute a heterogeneous group of patients. Depending on previous treatment, women with recurrent endometrial cancer may be appropriate candidates for surgery, radiation therapy, hormonal therapy, or chemotherapy. Women with advanced stage disease at presentation may also be appropriate candidates for systemic and local therapies. We review the treatment options available to treat recurrent and locally advanced endometrial cancer. Treatment choice depends largely on the localization of disease, the patient's performance status and previous treatment history, as well the tumor's hormonal receptor status. Radiation therapy is appropriate for isolated vaginal recurrences in patients with no previous history of radiation therapy. Patients with recurrent low-grade tumors overexpressing estrogen and progesterone receptors may be treated with progestin therapy. Systemic therapy is appropriate for patients with disseminate recurrences or advanced stage disease at presentation, or for those with receptor-negative tumors. We review all these different treatment strategies available to patients with advanced or recurrent endometrial cancer.Keywords
This publication has 75 references indexed in Scilit:
- Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group studyGynecologic Oncology, 2010
- An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A gynecologic oncology group studyGynecologic Oncology, 2008
- Major Progress for a Less Common CancerJournal of Clinical Oncology, 2006
- The Phosphoinositide 3-Kinase PathwayScience, 2002
- Consolidation Radiotherapy after Carboplatin-Based Chemotherapy in Radically Operated Advanced Ovarian CancerGynecologic Oncology, 1999
- Maximal Cytoreductive Surgery as a Reasonable Therapeutic Alternative for Recurrent Endometrial CarcinomaGynecologic Oncology, 1998
- Isolated Vaginal Recurrences in Endometrial Carcinoma: Treatment Results Using High-Dose-Rate Intracavitary Brachytherapy and External Beam RadiotherapyGynecologic Oncology, 1997
- Endometrial carcinoma: Steroid receptors and response to medroxyprogesterone acetateGynecologic Oncology, 1985
- The use of megestrol acetate in the treatment of advanced malignant lesions of the endometriumGynecologic Oncology, 1973
- Medroxyprogesterone in the management of primary and recurrent or metastatic uterine adenocarcinomaActa Obstetricia et Gynecologica Scandinavica, 1972